



Figure S1. YAP/TAZ are required for primary chondrocyte proliferation *in vitro*, but are not required to prevent apoptosis.

- A) Primary chondrocyte cultures from ribcages and sterna of wild-type or *Col2a1cre*<sup>\*\*\*</sup> P0 pups plated at low density (3000 cells per well).
- B) Proliferation, measured by confluence (percentage cell coverage) of field of view, of cultures from A). Data represent average of individual pups (biological replicates), the averages of which were derived from 6 wells (technical replicates). n = 3 wild-type and 5  $Col2a1cre^{-ve}$  P0 pups. Linear growth phase was measured by linear mixed model.
- C-E) Levels of apoptosis, measured by confluence (percentage cell coverage) of field of view of apoptotic cells stained with NucView488 as a percentage of total cell confluence. Data represent C) 9 technical replicates per indicated genotype; D) 3 *nls-YAP5SA<sup>KIIII</sup>-Col2a1creERT<sup>AVE</sup>* biological replicates treated with 1 uM 4-hydroxytamoxifen (4-OHT) or ethanol vehicle (EtOH) at 24 hr after plating; E) 3 wild-type and 5 *Col2a1cre<sup>AVE</sup>* biological replicates. Data were analysed by two-way ANOVA, with time elapsed and genotype as the independent variables, percentage apoptotic cells as the dependent variable. The effect of genotype on percentage apoptotic cells was not significant in any scenario. Scale bar = 150  $\mu$ m (A).
- F) Quantification of cell numbers following *in vitro* culture of primary chondrocytes from control ( $Col2a1cre^{-ve}$ ), Yap/Taz double homozygous floxed animals, and nlsYap5SA-expressing animals. Related to Figure 1






Chi squared: p = 0.0006


Chi-square test: p = 0.1529

Chi squared: p = 0.2006



## Figure S2. Yap/Taz double conditional mutants are not present at weaning owing to cleft palate.

Scale bar = 0.5 mm.



## Figure S3. Growth plate expression of YAP and TAZ in control and dKO growth plates and no change in apoptosis in dKO growth plates.

- A) AP immunostaining (green) is present in the nucleus and cytoplasm of control tibial growth plates but not in the *Yap/Taz* double homozygous floxed animals in the presence of *Col2a1cre*. DAPI (purple) marks nuclei.
- B) TAZ immunostaining (brown) is present in the nucleus and cytoplasm of control tibial growth plates but not in the *Yap/Taz* double homozygous floxed animals in the presence of *Col2a1cre*. Eosin (light blue) marks nuclei.
- C) TUNEL staining of proximal growth plate of the tibia of E17.5 control ( $Col2a1cre^{**e}$ ) and  $Yap^*mTaz^*mCol2a1cre^{**e}$  pups and control ( $Col2a1cre^{**e}$ ) and  $nls-YAP5SA^*m+Col2a1cre^{**e}$  pups. Images are representative of n=4 control ( $Col2a1cre^{**e}$ ), n=4  $Yap^*mTaz^*mCol2a1cre^{**e}$  and n=3  $nls-YAP5SA^*m+Col2a1cre^{**e}$  E17.5 tibial growth plates. Scale bar = 200  $\mu$ m





Figure S4. The Col2a1cre allele does not affect tibial growth plate zone size.

- A) Tibial growth plates from both Wild-type and Col2a1cre-positive animals show no differences in growth plate size.
- B) Quantification of zone lengths in A.



## Figure S5. Chondrocyte marker expression in YAP/TAZ-modulated chondrocytes

- A) Cartilage-specific double knockout of Yap/Taz does not affect expression of SOX9 or COLX in tibial growth plates.
- B) Cartilage-specific double knockout of Yap/Taz increases the length of the immunostained domains in growth plates, consistent with reduced cell density.
- C) Cartilage-specific expression of active nlsYAP<sup>5SA</sup> does not affect expression of SOX9 or COLX in tibial growth plates.
- D) Cartilage-specific expression of active nlsYAP<sup>5SA</sup> decreases the length of the immunostained domains in growth plates, consistent with increased cell density.
- E) Cartilage-specific double knockout of *Lats1/2* reduces overall size and reduces SOX9 expression levels, which may reflect a very strong activation of both YAP and TAZ.

**Table S1: Primers for RTqPCR** 

| Gene name | Primer sequences/Catalogue number    | Source           |
|-----------|--------------------------------------|------------------|
| Yap*      | QuantiTect: QT01061130               | Qiagen           |
| Taz       | Fwd: 5'-GGGTTAGGGTGCTACAGTGT-3'      | This study       |
|           | Rev: 5'-CTGACCGGAATTTTCACCTGT-3'     | -                |
| Sox6      | Fwd: 5'-GGAGATGCGACAGTTCTTCAC-3'     | This study       |
|           | Rev: 5'-TCTGAGGTGATGGTGTGGTC-3'      |                  |
| Sox9      | Fwd: 5'-GACTCCCCACATTCCTCCTC-3'      | This study       |
|           | Rev: 5'-CTGCTCAGTTCACCGATGTC-3'      |                  |
| Ctgf      | QuantiTect: QT00096131               | Qiagen           |
| Cyr61     | QuantiTect: QT00245217               | Qiagen           |
| Acan      | QuantiTect: QT00175364               | Qiagen           |
| Comp      | Fwd: 5'-CCTGGGTGTCTTCTGCTTCT-3'      | This study       |
|           | Rev: 5'-CCCTAGACTCTCTGCAGCC-3'       | -                |
| Col2a1    | Fwd: 5'-AAGTCACTGAACAACCAGATTGAGA-3' | Shea et al, 2019 |
|           | Rev: 5'-AAGTGCGAGCAGGGTTCTTG-3'      |                  |
| Col10a1   | Fwd: 5'-TGCAATCATGGAGCTCACAGA-3'     | Shea et al, 2019 |
|           | Rev: 5'-CAGAGGAGTAGAGGCCGTTTGA-2'    |                  |
| Mmp2      | Fwd: 5'-GATGCTGCCTTTAACTGGAGT-3'     | This study       |
|           | Rev: 5'-ACCGGGGTCCATTTTCTTCT-3'      |                  |
| Mmp14     | Fwd: 5'-GGGTCATTCATGGGCAGTGA-3'      | This study       |
|           | Rev: 5'-CGCAGAGCTGACTTGGGATA-3'      |                  |
| Mmp16     | Fwd: 5'-GGTGGGAAGATGTTGGCAAA-3'      | This study       |
|           | Rev: 5'-GGTGATGGGCTTGGGGTAA-3'       |                  |
| Ctsk      | Fwd: 5'-CAGAAGGGAAGCAAGCACTG-3'      | This study       |
|           | Rev: 5'-ATTCCGAGCCAAGAGAGCAT-3'      |                  |
| Hsp90ab1  | Fwd: 5'-AGAATCCGACACCAAACTGC-3'      | Voss et al.,     |
|           | Rev: 5'-ACCTGGGAACCATTGCTAAG-3'      | 2012             |

<sup>\*</sup>Whilst this primer is listed as mouse-specific, we observed cross-reactivity with the human YAP sequence.

## Vanyai et al Supplementary References

Shea, C.A., Rolfe, R.A., McNeill, H., and Murphy, P. (2020). Localization of YAP activity in developing skeletal rudiments is responsive to mechanical stimulation. Dev Dyn *249*, 523-542.

Voss, A.K., Vanyai, H.K., Collin, C., Dixon, M.P., McLennan, T.J., Sheikh, B.N., Scambler, P., and Thomas, T. (2012). MOZ regulates the Tbx1 locus, and Moz mutation partially phenocopies DiGeorge syndrome. Dev Cell *23*, 652-663.